Drug Profile

Florbetaben - Lantheus Holdings

Alternative Names: LNTH-2515

Latest Information Update: 28 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Phase III Amyloid light-chain amyloidosis; Transthyretin-related hereditary amyloidosis

04 Nov 2025 Phase-III clinical trials in Amyloid light-chain amyloidosis (Diagnosis) (unspecified route) (Lantheus Holdings pipeline, October 2025)
04 Nov 2025 Phase-III clinical trials in Transthyretin-related hereditary amyloidosis (Diagnosis) (unspecified route) (Lantheus Holdings pipeline, October 2025)
04 Nov 2025 Florbetaben - Lantheus Holdings receives Fast Track designation for Amyloid light-chain amyloidosis (Diagnosis) in Unknown (Lantheus Holdings pipeline, October 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com